CCND1 and pachyonychia congenita: Several studies have demonstrated changes in cyclin D1 expression, both in the early stage and along tumor progression, in different types of cancers, including breast [10], head and neck [11], prostate [12] and renal cell carcinoma [13] and PC [14].